ATE382364T1 - Von igf-bindungsprotein stammendes peptid - Google Patents
Von igf-bindungsprotein stammendes peptidInfo
- Publication number
- ATE382364T1 ATE382364T1 AT02759330T AT02759330T ATE382364T1 AT E382364 T1 ATE382364 T1 AT E382364T1 AT 02759330 T AT02759330 T AT 02759330T AT 02759330 T AT02759330 T AT 02759330T AT E382364 T1 ATE382364 T1 AT E382364T1
- Authority
- AT
- Austria
- Prior art keywords
- binding protein
- peptide derived
- igf binding
- disease
- new
- Prior art date
Links
- 102000028416 insulin-like growth factor binding Human genes 0.000 title abstract 2
- 108091022911 insulin-like growth factor binding Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32326701P | 2001-09-18 | 2001-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE382364T1 true ATE382364T1 (de) | 2008-01-15 |
Family
ID=23258422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02759330T ATE382364T1 (de) | 2001-09-18 | 2002-08-09 | Von igf-bindungsprotein stammendes peptid |
Country Status (9)
Country | Link |
---|---|
US (1) | US6861406B2 (de) |
EP (1) | EP1435986B1 (de) |
JP (1) | JP4344242B2 (de) |
AT (1) | ATE382364T1 (de) |
AU (1) | AU2002324672B2 (de) |
CA (1) | CA2460719A1 (de) |
DE (1) | DE60224419D1 (de) |
HK (1) | HK1062923A1 (de) |
WO (1) | WO2003025121A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8070796B2 (en) * | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7967855B2 (en) * | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
WO2005110493A2 (en) * | 2004-04-16 | 2005-11-24 | Bioexpertise Llc | Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress |
US6914049B2 (en) * | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
US8740973B2 (en) * | 2001-10-26 | 2014-06-03 | Icon Medical Corp. | Polymer biodegradable medical device |
EP1670822A2 (de) | 2003-10-03 | 2006-06-21 | Genentech, Inc. | Igf-bindende proteine |
US20060084603A1 (en) * | 2004-08-06 | 2006-04-20 | Irena Kirman | IGF-BP3-related methods for inhibiting tumor growth |
US7455688B2 (en) | 2004-11-12 | 2008-11-25 | Con Interventional Systems, Inc. | Ostial stent |
US9339403B2 (en) * | 2004-11-12 | 2016-05-17 | Icon Medical Corp. | Medical adhesive for medical devices |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20060198869A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Bioabsorable medical devices |
EP1858440B1 (de) * | 2005-03-03 | 2024-04-24 | MiRus LLC | Verbesserte metalllegierungen für ein medizinprodukt |
WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US7611893B2 (en) | 2005-11-09 | 2009-11-03 | Ontherix, Inc. | Metal-binding therapeutic peptides |
US7662624B2 (en) * | 2005-11-09 | 2010-02-16 | Ontherix, Inc. | Metal-binding therapeutic peptides |
WO2007056511A2 (en) * | 2005-11-09 | 2007-05-18 | Ontherix, Inc. | Metal-binding therapeutic peptides |
US20080039393A1 (en) * | 2005-11-09 | 2008-02-14 | Desmond Mascarenhas | Metal-binding therapeutic peptides |
WO2008008291A2 (en) * | 2006-07-13 | 2008-01-17 | Icon Medical Corp. | Stent |
WO2008086813A2 (en) * | 2007-01-19 | 2008-07-24 | Kobenhavns Universitet | Peptides derived from proteins of the insulin super-family |
US8536135B2 (en) * | 2008-03-19 | 2013-09-17 | Ontherix, Inc. | Adaptive biochemical signatures |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
US11266767B2 (en) | 2014-06-24 | 2022-03-08 | Mirus Llc | Metal alloys for medical devices |
WO2017026505A1 (ja) * | 2015-08-11 | 2017-02-16 | 池田食研株式会社 | 結合剤 |
WO2017151548A1 (en) | 2016-03-04 | 2017-09-08 | Mirus Llc | Stent device for spinal fusion |
US11312766B2 (en) * | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
US5200509A (en) | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
US5187151A (en) | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
DE69218948T2 (de) * | 1991-08-01 | 1997-07-31 | Auckland Uniservices Ltd | IGF-I zur Verbesserung der neuronale Lage |
US5407913A (en) | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
US5643867A (en) | 1992-08-26 | 1997-07-01 | Celtrix Pharmaceuticals, Inc. | Method for treating catabolic conditions |
US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
WO1995003817A1 (en) | 1993-08-03 | 1995-02-09 | Celtrix Pharmaceuticals, Inc. | Method of treating reproductive disorders |
EP0726911B1 (de) | 1993-09-20 | 2002-10-30 | Celtrix Pharmaceuticals, Inc. | Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex |
EP0732933B1 (de) | 1993-11-15 | 2002-10-09 | Celtrix Pharmaceuticals, Inc. | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung |
JPH09509140A (ja) | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
US5861273A (en) | 1993-12-21 | 1999-01-19 | Celtrix Phamraceuticals, Inc. | Chromosomal expression of heterologous genes in bacterial cells |
AUPM672594A0 (en) | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
AU713275B2 (en) | 1994-07-20 | 1999-11-25 | Celtrix Pharmaceuticals, Inc. | IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling |
CA2232000A1 (en) | 1995-09-14 | 1997-03-20 | Bristol-Myers Squibb Company | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
US6015786A (en) | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
US6417330B1 (en) | 1998-06-01 | 2002-07-09 | Celtrix Pharmaceuticals, Inc. | Insulin-like growth factor binding protein variants |
WO2000023469A2 (en) * | 1998-10-16 | 2000-04-27 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
CA2410056A1 (en) | 2000-05-17 | 2001-11-22 | Oregon Health Science University | Induction of apoptosis and cell growth inhibition by protein 4.33 |
US20030035788A1 (en) | 2000-09-19 | 2003-02-20 | Desmond Mascarenhas | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
AU2002232593A1 (en) | 2000-10-27 | 2002-05-06 | Oregon Health And Science University | Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor |
ATE439378T1 (de) | 2001-02-09 | 2009-08-15 | Genentech Inc | Verfahren zur identifizierung von indirekten igf- 1-agonisten |
AU2002248609B2 (en) | 2001-03-14 | 2007-03-01 | Genentech, Inc. | IGF antagonist peptides |
-
2002
- 2002-08-09 AU AU2002324672A patent/AU2002324672B2/en not_active Ceased
- 2002-08-09 DE DE60224419T patent/DE60224419D1/de not_active Expired - Lifetime
- 2002-08-09 US US10/215,759 patent/US6861406B2/en not_active Expired - Lifetime
- 2002-08-09 CA CA002460719A patent/CA2460719A1/en not_active Abandoned
- 2002-08-09 WO PCT/US2002/025532 patent/WO2003025121A2/en active IP Right Grant
- 2002-08-09 EP EP02759330A patent/EP1435986B1/de not_active Expired - Lifetime
- 2002-08-09 AT AT02759330T patent/ATE382364T1/de not_active IP Right Cessation
- 2002-08-09 JP JP2003529895A patent/JP4344242B2/ja not_active Expired - Fee Related
-
2004
- 2004-08-04 HK HK04105749A patent/HK1062923A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002324672B2 (en) | 2007-11-08 |
DE60224419D1 (de) | 2008-02-14 |
EP1435986A2 (de) | 2004-07-14 |
JP2005504801A (ja) | 2005-02-17 |
CA2460719A1 (en) | 2003-03-27 |
WO2003025121A3 (en) | 2004-01-22 |
EP1435986B1 (de) | 2008-01-02 |
JP4344242B2 (ja) | 2009-10-14 |
EP1435986A4 (de) | 2006-01-11 |
HK1062923A1 (en) | 2004-12-03 |
WO2003025121A2 (en) | 2003-03-27 |
US20030059430A1 (en) | 2003-03-27 |
US6861406B2 (en) | 2005-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE382364T1 (de) | Von igf-bindungsprotein stammendes peptid | |
WO2004033481A3 (en) | Igf-binding protein-derived peptide or small molecule | |
WO2004080405A3 (en) | Igf-binding protein-derived peptide or small molecule | |
DE602004029812D1 (de) | Fgf-5-bindende und geträgerte peptide | |
CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
MXPA05010830A (es) | Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana. | |
DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
DK1673475T3 (da) | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt | |
EA200601074A1 (ru) | Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли) | |
RS92704A (en) | Immunoglobulin-domain containing cell surface recognition molecules | |
NO20052956D0 (no) | Defensinprotiner | |
EP1071443A4 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
WO2004076614A3 (de) | Humane nukleinsäuresequenzen aus prostatakarzinomen | |
WO2004096856A3 (en) | Secreted protein family | |
DK1387854T3 (da) | SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf | |
DE69836333D1 (de) | Neisseria lactoferrin-bindendes protein | |
EA200700990A1 (ru) | Новые пептиды, которые связывают рецептор эритропоэтина | |
EA200600956A1 (ru) | Молекулы-антагонисты цитокинов | |
NO20052525L (no) | Spleisevariant av humant hypofyseveksthormon | |
ATE512983T1 (de) | Rezeptor für das tgr3-like protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |